Adarx Pharmaceuticals, Inc.

This study tests a new medicine called ADX-324 for people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. The drug uses a technology called siRNA to lower a protein involved in triggering attacks. About 90 adults with HAE type 1 or 2 wi…

This study tests an investigational drug called ADX-038 in 240 people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. The drug is given as a shot under the skin and is compared to a placebo to see if it can slow the loss …

This study tests a new drug called ADX-038 for people with PNH who still have anemia despite treatment. It first checks safety in healthy adults, then tests the drug in PNH patients. The goal is to see if ADX-038 can safely control the disease and improve red blood cell health.

This study tests a new drug called ADX-038 in 30 Chinese adults with kidney diseases caused by the immune system attacking the kidneys (IgA nephropathy, C3G, or IC-MPGN). The goal is to see if the drug is safe and can help control the disease, either alone or with another medicat…

This study is for people with hereditary angioedema (HAE) who finished a previous phase 3 trial of ADX-324. It aims to see if the drug is safe and can prevent swelling attacks over a longer period. About 90 participants will receive additional doses of ADX-324 and be monitored fo…

This study tests a new drug called ADX-038 in 45 adults with kidney diseases caused by an overactive complement system (part of the immune system), including IgA nephropathy and C3G. The goal is to see if the drug is safe and can help control the disease. Participants must have a…

This early-stage study tests the safety of a new drug called ADX-626 in 44 healthy adults aged 18 to 45. Researchers will monitor side effects and measure how the drug moves through the body. No treatment benefit is expected; the goal is to gather essential safety data before tes…